Posted by Michael Wonder on 19 Nov 2022
European Commission approves Enjaymo (sutimlimab) for treatment of haemolytic anaemia in adult patients with cold agglutinin disease
17 November 2022 - Enjaymo is the first and only approved therapeutic option approved for haemolytic anaemia in adult patients with cold agglutinin disease
The European Commission has granted marketing authorisation for Enjaymo (sutimlimab) for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease, a rare, serious, and chronic auto-immune haemolytic anaemia, where the body’s immune system mistakenly attacks healthy red blood cells and causes their rupture, known as haemolysis.
